Tibet AIM Pharm. Inc. (SHE:002826)
17.70
-0.39 (-2.16%)
Sep 10, 2026, 3:04 PM CST
Tibet AIM Pharm. Revenue
Tibet AIM Pharm. had revenue of 177.05M CNY in the quarter ending June 30, 2026, with 8.67% growth. This brings the company's revenue in the last twelve months to 684.45M, up 11.96% year-over-year. In the year 2025, Tibet AIM Pharm. had annual revenue of 636.27M, down -2.39%.
Revenue (ttm)
684.45M
Revenue Growth
+11.96%
P/S Ratio
5.02
Revenue / Employee
1.69M
Employees
405
Market Cap
3.44B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 636.27M | -15.61M | -2.39% |
| Dec 31, 2024 | 651.88M | -15.16M | -2.27% |
| Dec 31, 2023 | 667.04M | -189.70M | -22.14% |
| Jan 1, 2023 | 856.73M | 131.28M | 18.10% |
| Jan 1, 2022 | 725.46M | 122.84M | 20.38% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Well Pharmaceutical Group | 1.40B |
| Zhuhai Rundu Pharmaceutical | 1.34B |
| Huaren Pharmaceutical | 1.30B |
| PKU HealthCare Corp.,Ltd. | 972.17M |
| Zhejiang Cheng Yi Pharmaceutical | 827.47M |
| Wuhan Hiteck Biological Pharma Co.,Ltd | 491.90M |
| Lionco Pharmaceutical Group | 408.33M |
| Hainan Shuangcheng Pharmaceuticals | 309.80M |